[go: up one dir, main page]

HK102894A - Orthorhombic ciclosporin crystal form,process for its production and pharmaceutical compositions containing it - Google Patents

Orthorhombic ciclosporin crystal form,process for its production and pharmaceutical compositions containing it Download PDF

Info

Publication number
HK102894A
HK102894A HK102894A HK102894A HK102894A HK 102894 A HK102894 A HK 102894A HK 102894 A HK102894 A HK 102894A HK 102894 A HK102894 A HK 102894A HK 102894 A HK102894 A HK 102894A
Authority
HK
Hong Kong
Prior art keywords
ciclosporin
crystal form
production
pharmaceutical compositions
orthorhombic
Prior art date
Application number
HK102894A
Inventor
Giron Danielle
List Martin
Richter Friedrich
Ulke Yasuyuki
Peter Weber Hans
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK102894A publication Critical patent/HK102894A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

NOVEL PHARMACEUTICAL COMPOSITIONS, IN PARTICULAR TOPICAL FORMS, E.G. FOR DERMAL OR TOPICAL OPHTHALMIC USE, AND INJECTIBLE FORMS, E.G. FOR INTRA-LESIONAL OR INTRA-ARTICULAR INJECTION, COMPRISING CICLOSPORIN AS ACTIVE INGREDIENT IN ORTHORHOMBIC CRYSTAL FORM. CICLOSPORIN IN NON-SOLVATE ORTHORHOMBIC CRYSTAL FORM IS PREFERRED FOR USE IN THE COMPOSITIONS OF THE INVENTION, IS NEW AND ALSO PART OF THE INVENTION, TOGETHER WITH ITS USE AND PROCESSES FOR ITS PRODUCTION.
HK102894A 1987-12-21 1994-09-22 Orthorhombic ciclosporin crystal form,process for its production and pharmaceutical compositions containing it HK102894A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13623087A 1987-12-21 1987-12-21
US17261388A 1988-03-24 1988-03-24
US21254888A 1988-06-28 1988-06-28

Publications (1)

Publication Number Publication Date
HK102894A true HK102894A (en) 1994-09-30

Family

ID=27384838

Family Applications (1)

Application Number Title Priority Date Filing Date
HK102894A HK102894A (en) 1987-12-21 1994-09-22 Orthorhombic ciclosporin crystal form,process for its production and pharmaceutical compositions containing it

Country Status (27)

Country Link
JP (1) JPH0791316B2 (en)
KR (1) KR100188305B1 (en)
AT (1) AT403163B (en)
AU (1) AU626274B2 (en)
BE (1) BE1002665A4 (en)
CA (1) CA1341396C (en)
CH (1) CH677926A5 (en)
CY (1) CY1799A (en)
DE (1) DE3843054C2 (en)
DK (1) DK175220B1 (en)
ES (1) ES2012580A6 (en)
FI (1) FI89065C (en)
FR (1) FR2624863B1 (en)
GB (1) GB2211848B (en)
GR (1) GR1002486B (en)
HK (1) HK102894A (en)
HU (1) HU203564B (en)
IE (1) IE62006B1 (en)
IL (1) IL88719A0 (en)
IT (1) IT1235356B (en)
LU (1) LU87409A1 (en)
MY (1) MY103943A (en)
NL (1) NL195096C (en)
NO (1) NO177228C (en)
NZ (1) NZ227384A (en)
SE (1) SE503174C2 (en)
SG (1) SG99494G (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US7081445B2 (en) 1989-02-20 2006-07-25 Novartis Ag Cyclosporin galenic forms
US5294604A (en) * 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
GB9105705D0 (en) * 1991-03-18 1991-05-01 Sandoz Ltd Improvements in or relating to organic compounds
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
EP0642332B1 (en) * 1992-05-13 1997-01-15 Sandoz Ltd. Ophthalmic compositions containing a cyclosporin
ES2168271T3 (en) 1992-09-25 2002-06-16 Novartis Ag PHARMACEUTICAL COMPOSITIONS CONTAINING CYCLOSPORINS.
PT789580E (en) 1994-11-03 2002-09-30 Novartis Ag CYCLOSPORINE FORMULATIONS FOR ORAL ADMINISTRATION WITH SIMPLE COMPOSITION AND HIGH BIODISPONIBILITY AND PROCESS FOR ITS PRODUCTION
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
DE19549852B4 (en) 1995-11-29 2009-06-04 Novartis Ag Cyclosporin containing preparations
US6262054B1 (en) * 1996-02-01 2001-07-17 Sloan-Kettering Institute Of Cancer Research Combination therapy method for treating breast cancer using edatrexate
EP0988046B1 (en) 1997-01-30 2004-09-15 Novartis AG Oil-free pharmaceutical compositions containing cyclosporin a
TW581681B (en) 1998-02-20 2004-04-01 Nektar Therapeutics Liquid crystal forms of cyclosporin
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
JP2007518804A (en) 2004-01-20 2007-07-12 アラーガン、インコーポレイテッド Composition for topical ophthalmic treatment preferably containing triamcinolone acetonide and hyaluronic acid
CN1763084B (en) * 2005-10-11 2010-04-21 山东新时代药业有限公司 Preparation method of high-purity cyclosporine A
CA2836946C (en) * 2011-05-27 2017-08-01 Allergan, Inc. A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
BR112014011744A2 (en) 2011-11-15 2017-05-02 Allergan Inc sustainable action formulation of cyclosporine form 2
RU2630970C2 (en) 2011-11-15 2017-09-15 Аллерган, Инк. Autoclavable form 2 cyclosporin a portion
EP2779994B1 (en) * 2011-11-15 2020-02-19 Allergan, Inc. Suspensions of cyclosporin a form 2
WO2013074608A1 (en) 2011-11-15 2013-05-23 Allergan, Inc. Cyclosporine a form 2 and method of making same
WO2024085235A1 (en) * 2022-10-20 2024-04-25 中外製薬株式会社 Method for producing cyclic peptide crystals

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH614931A5 (en) * 1975-11-04 1979-12-28 Sandoz Ag
CH640519A5 (en) * 1976-04-09 1984-01-13 Sandoz Ag Process for preparing a modified form of the antibiotic S 7481/F-1
US4117118A (en) * 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
DE2819094A1 (en) * 1977-05-10 1978-11-23 Sandoz Ag CYCLOSPORIN DERIVATIVES, THEIR USE AND MANUFACTURING
CH637124A5 (en) * 1978-10-18 1983-07-15 Sandoz Ag Antibiotic, its preparation and use

Also Published As

Publication number Publication date
IE883779L (en) 1989-06-21
IE62006B1 (en) 1994-12-14
NO177228B (en) 1995-05-02
DK705488A (en) 1989-06-22
GB2211848B (en) 1991-11-06
SE8804570D0 (en) 1988-12-19
CH677926A5 (en) 1991-07-15
IT1235356B (en) 1992-06-30
FR2624863B1 (en) 1991-04-26
DK705488D0 (en) 1988-12-19
AT403163B (en) 1997-11-25
HUT49893A (en) 1989-11-28
FR2624863A1 (en) 1989-06-23
JPH0791316B2 (en) 1995-10-04
GR1002486B (en) 1996-12-09
HU203564B (en) 1991-08-28
ES2012580A6 (en) 1990-04-01
KR100188305B1 (en) 1999-06-01
GB2211848A (en) 1989-07-12
NL195096C (en) 2004-02-09
AU2705588A (en) 1989-06-22
NO885625L (en) 1989-06-22
IT8848690A0 (en) 1988-12-20
AU626274B2 (en) 1992-07-30
GR880100850A (en) 1994-03-31
SG99494G (en) 1994-10-28
GB8829556D0 (en) 1989-02-08
IL88719A0 (en) 1989-07-31
MY103943A (en) 1993-10-30
JPH01211598A (en) 1989-08-24
NL8803125A (en) 1989-07-17
CY1799A (en) 1995-02-17
KR890009975A (en) 1989-08-05
NO177228C (en) 1995-08-09
ATA309588A (en) 1997-04-15
SE503174C2 (en) 1996-04-15
NZ227384A (en) 1991-09-25
BE1002665A4 (en) 1991-04-30
DE3843054A1 (en) 1989-07-27
DE3843054C2 (en) 2003-08-21
NO885625D0 (en) 1988-12-19
CA1341396C (en) 2002-11-05
FI89065C (en) 1993-09-30
LU87409A1 (en) 1989-07-07
SE8804570L (en) 1989-06-22
DK175220B1 (en) 2004-07-12
FI885869L (en) 1989-06-22
FI89065B (en) 1993-04-30
FI885869A0 (en) 1988-12-19

Similar Documents

Publication Publication Date Title
HK102894A (en) Orthorhombic ciclosporin crystal form,process for its production and pharmaceutical compositions containing it
IE891798L (en) Novel ó-glucosidase inhibitors
CA2000786A1 (en) 3-piperidinyl-1,2-benzisoxazoles
PH31617A (en) Novel thienylcarboxylates of amino alcohols, theirquaternary products and use of these compounds.
EP0142426A3 (en) Ophthalmic formulation containing norfloxacin and related antibiotics
EP0374440A3 (en) Inhibitors of lysyl oxidase
EG18379A (en) Novel pharmacological compounds
ES479474A1 (en) Use of 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridin-3-beta-methoxy ethylester-5-isopropylester for the preparation of cerebrally active drugs.
UA29450C2 (en) Derivatives of hydroxamic acid, a PROCESS for PREPARATION thereof, a method for influence on diseases and pharmaceutical composition containing them
CA2148928A1 (en) Pharmacologically active pyridine derivatives and processes for the preparation thereof
GEP20022636B (en) 4-[5-Methyl-3-Phenylisoxazol-4-Yl] Benzenesulfonamide, Its Crystal Structure B, Pharmaceutical Composition Containing The Same, Methods For Treatment Or Prophylaxis Of Disorders Caused By Cyclooxygen-2
HU9502588D0 (en) Heterocyclic compounds and their preparation and use
EP1167354A3 (en) Racemic huperzine A
CA2163118A1 (en) Aurintricaboxylic Acid Fractions and Analogues with Anti-Angiogenic Activity and Methods of Use
HUT58765A (en) Process for producing peptide compounds and pharmaceutical compositions containing them as active components
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
CA2047802A1 (en) Pharmaceutical compositions
EP0378413A3 (en) Compositions for topical treatment of skin disorders
HUT47124A (en) Process for producing pharmaceutical compositions comprising organic platinum complex as active ingredient and the active ingredients
IE870577L (en) Topical amide preparation
EP0273310A3 (en) 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
CA2138793A1 (en) Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections
ES447307A1 (en) Novel process for the preparation of 1-N-(alpha-substituted-omega-aminoacyl)-3{40 -deoxyribostamycin
EP0386920A3 (en) 2-hydroxy-3-thienyloxypropylamino derivatives
WO2001028578A3 (en) A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20081218